Lilly Forteo
Executive Summary
FDA Endocrinologic & Metabolic Drugs Advisory Committee will review osteoporosis drug teriparatide this summer, Lilly tells Deutsche Bank Alex Brown 2001 healthcare conference May 9 in Baltimore. The committee is tentatively scheduled to meet July 26-27. Forteo Phase III trial results were published in The New England Journal of Medicine May 10. The publication could have coincided with approval of the drug if it had received a priority review; FDA, however, designated it as a standard NDA
You may also be interested in...
Lilly Forteo
FDA Endocrinologic & Metabolic Drugs Advisory Committee will review teriparatide (NDA 21-318) July 27 for the treatment of osteoporosis in post-menopausal women and in men (1"The Pink Sheet" May 14, In Brief). The committee will meet at 8 a.m. at the Holiday Inn in Bethesda, Md
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011